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CHAPTER I 
INTRODUCTION AND REVIEW OF LITERATURE 
Biotransformation of Xenobiotics 
Biotransformation or metabolism is a process by 'Which a foreign 
chemical is subjected to chemical change by an animal's hepatic drug 
metabolizing enzyme system. Biotransformation is usually a biphasic process 
in which the initial phase (phase I) consists of oxidative, reductive, or hydrolytic 
reactions. These reactions transform a drug by exposing existing polar groups 
or introducing into the drug molecule, functional groups such as -OH or = 0 . 
These functional groups enable the compound to undergo synthetic or 
conjugation reactions in phase II. Conjugation involves endogenous substances 
such as glucuronic acid, acetate (acetylation), sulfate {sulfuric acid ester 
formation) and various amino acids which react with xenobiotics resulting in the 
formation of water soluble conjugated products. These products are excreted 
by transfer across hepatic, renal, and intestinal membranes. The excretion of 
conjugated drugs is enhanced by their ability to bind to transport carriers (Sipes 
& Gandolfi, 1986}. 
The liver is the major site of biotransformation for many xenobiotics. 
However, other tissues such as lung, kidney, placenta, white blood cells, and 
gut may play an important role in metabolism. Most phase I reactions are 
1 
2 
catalyzed or mediated by microsomal enzyme .systems located in the ;smooth 
endoplasmic reticulum of hepatocytes. Microsomal enzyme systems are 
composed of mixed-function oxidases of which cytochrome P-450 are 
predominant. When reduced, cytochrome P-450 (f!e2 +) forms a ligand with 
carbon monoxide and maximally absorbs light at 450 nm. Thus the name 
cytochrome P-450 was derived. Microsomal cytochrome P-450 are 
hemeproteins with a prosthetic group containing iron. This group forms 
coordinate bonds by sharing electrons with the four nitrogen atoms of a 
tetrapyrrole ring and two other ligands. The ligands are a thiolate anion and 
either oxygen, carbon monoxide, or cyanide. The apparent monomeric 
molecular weight of cytochrome P-450 enzymes is 45,000 to 60,000 
(Guengerich & Liebler, 1985; Sipes & Gandolfi, 1986; Riviere & Cabanne, 
1987). 
NADPH-cytochrome P-450 reductase and cytochrome P-450 comprise 
the enzyme system. Also associated with the reaction are cytochrome b5 and 
cytochrome b5 reductase, but the function of cytochrome b5 and its associated 
reductase in the cytochrome P-450 mediated reaction has not been clearly 
established. This reaction occurs when substrate (RH) combines w ith 
cytochrome P-450 (Fe3 +) in an oxidized state to form a substrate-cytochrome 
P-450 complex. The complex then accepts an electron from NADPH, following 
which NADPH-cytochrome P-450 reductase is released. This results in 
reduction of iron in cytochrome P-450 heme moiety to Fe2+. After combining 
with molecular oxygen, oxygenated substrate-cytochrome P-450 complex 
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accepts another electron .from NADPH via cytochrome b5· reductase. Both 
electrons are thought to be transferred to molecular oxygen resulting :in an 
unstable and highly reactive oxygen.species. One of the reactive oxygen atoms 
is reduced to water, while the other is introduced into the substrate. The 
oxidized form of cytochrome P-450 ·is regenerated after dissociating from the 
oxygenated substrate (Figure 1 )(Sipes & Gandolfi, J 986). 
Substrates of cytochrome P-450 can be divided into endogenous and 
exogenous compounds (xenobiotics). Endogenous compounds include fatty 
acids, prostaglandins, cholesterol, steroids, and lipid-soluble vitamins 
(hydroxylation of vitamin D). Examples of exogenous compounds are drugs, 
pesticides, and organic pollutants, which are mainly lipophilic (Riviere & 
Cabanne, 1987). 
In each animal species, the cytochrome P-450 occur in multiple isozymic 
forms differing with regard to the specificity of the reactions they catalyze and 
the rates of substrate metabolism. Different sites on a single compound may 
be metabolized by different isozymes and chemical stereoisomers may be 
metabolized differently by the various isozymes. Potentially toxic chemicals 
may be detoxified by one isozyme and bioactivated by another isozyme, or one 
isozyme can carry out both types of competing reactions. (Guengerich & 
Liebler, 1985). 
Individual isozymes can be induced or inhibited by xenobiotics, leading 
to an increase in catalytic activity of the isozymes (induction) or a decrease in 
activity (repression of hemoprotein synthesis, competitive or noncompetitive 
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inhibition, limited supply of a cofactor). Cytochromes that metabolize 
exogenous substrates are very sensitive to inducers (Riviere & Cabanne, 1987). 
A xenobiotic may also serve as a substrate for the same isozyme which it 
induces. The number of molecules of a specific enzyme can increase in 
response to an enzyme-inducing agent. The activity level of as many as seven 
different forms of P-450 can be increased by a xenobiotic while at the same 
time decreasing the activity level of another (Guengerich & Liebler, 1985). 
Pharmacologically, the induction of liver microsomal enzymes is important. As 
the rate of biotransformation is altered, so is the duration and intensity of drug 
action (Canney, 1967). There are several common features of enzyme inducing 
agents including; lipophilicity, ability to bind to cytochrome P-450 and relatively 
long biological half-life, however, not all agents that have these properties are 
enzyme inducers (Anadon, 1982). Polycyclic aromatic hydrocarbons, known 
inducers, enter cells and bind to cytosolic receptors. These agents are 
translocated to the nucleus where specific genes for transcription are activated. 
Activation increases the level of mRNA coding for individual P-450's. For an 
individual P-450's, the degree of induction by a single chemical can range from 
less than 2- to as much as 1 00-fold (Guengerich & Liebler, 1985). Treatment 
with phenobarbital, another known inducer, results in proliferation of the 
smooth endoplasmic reticulum and increased concentration of microsomal 
proteins (Sipes & Gandolfi, 1986). 
Phenobarbital and 3-methylcholanthrene-like compounds are the two 
traditional classes of inducers. Studies with pregnenolone-16a-carbonitrile 
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(PCN), isosafrole, and polyhalogenated biphenyls· indicate tbat the binary 
classification of inducers is too simplistic (Dannan et al, 1983h :The activity of 
hepatic microsomal enzymes have been shown to be stimulated by more that 
200 drugs, insecticides, carcinogens, and other chemicals. In the organism, 
there is no apparent characteristic pharmacological relationship between either 
the actions or chemical structures of these compounds and their ability to 
induce enzymes (Canney, 1967). The induction time course varies with the 
inducing agents.. Therapeutic doses of most inducing agents produce their 
maximum effect within 2 weeks. Rifampin, a potent inducer, can produce 
noticeable changes in activity of hepatic drug metabolizing enzymes within 48 
hours (Park & Breckenridge, 1981). Antipyrine, a much less potent inducer, 
can produce a change following administration for a period of 14 days 
(Ohnhaus et al, 1979; Ohnhaus & Park, 1979). 
Phenobarbital is characterized by its ability to stimulate the metabolism 
of a large number of substrates by various pathways. It has been 
demonstrated that administration of phenobarbital to laboratory animals 
increases the metabolism of the anticoagulant drugs, bishydroxycoumarin and 
warfarin. This results in a decreased anticoagulant effect of a given dose of 
these agents (Gelehrter, 1976). Phenobarbital differs from other enzyme 
inducing agents by increasing liver mass which is paralleled by an increase in 
liver blood flow (Park & Breckenridge, 1981 ). Phenobarbital decreases the 
storage of dieldrin (HEOD) in rat body fat probably by an induction of hepatic 
microsomal enzymes. HEOD is metabolized to a more polar compound that can 
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be excreted by the kidney . Phenobarbital has ··also been shown "to induce 
hepatic microsomal enzymes in ruminants indicating that 'it may increase the 
excretion rate of HEOD in cattle as well as rats (Cook & Wilson, 1970). 
Organophosphates act as indirect:inhibitors of cholinesterases. Hepatic 
microsomal enzymes may bioactivate thioorganophosphates to toxic analogues 
or detoxify them to inactive or less active compounds. The effect hepatic 
microsomal enzyme induction will have on the toxicity of a particular 
organophosphate is not predictable. Hepatic microsomal enzyme inducing 
agents have been found to increase hepatic carboxylesterase activity resulting 
in reduced toxicity of many organophosphates. In cattle, pretreatment with the 
hepatic microsomal enzyme inducers dieldrin and phenobarbital increased the 
toxic effect of diazinon and increased liver carboxylesterase activity. An 
increase in the toxicity of organophosphates such as guthion, azinophosmethyl, 
scharadon, and dimethoate have also been reported under similar conditions. 
Conversely, the toxicity of parathion, malathion, EPN, mipafox, demetilan, 
bidrin and phosphamidon was decreased following pretreatment with 
phenobarbital or dieldrin (Abdelsalam & Ford, 1986). 
Ethanol and rifampin are examples of other hepatic microsomal enzyme 
inducers. Chronic ethanol consumption increases the metabolism of ethanol 
and a variety of other drugs including tolbutamide, barbiturates, phenytoin, and 
warfarin. An increased tolerance of alcoholic patients to barbiturates and other 
sedatives may be accounted for by an increased rate of metabolism. Drug 
metabolism can also be inhibited by a single large dose of ethanol which may 
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account for the enhanced sensitivity to barbiturates-seen in intoxicated persons 
(Gelehrter, 1976). The antibiotic rifampin, a potent inducer, has been shown 
to increase cytochrome P-450 content of human liver ~.but does not influence 
liver blood flow. Elimination of a wide range of drugs has been reported to be 
accelerated by rifampin: antipyrine, warfarin, digitoxin, and cortisol. Rifampin 
has also been reported to stimulate its own clearance. (Park & Breckenridge, 
1981 ). 
The therapeutic implications of enzyme induction and inhibition depends 
largely on the relative biological activity of the drug and its metabolite(s) . In 
most cases the metabolites are therapeutically less active than the parent drug. 
Generally, the extent and duration of drug action are potentiated by enzyme 
inhibition and reduced by enzyme induction. These effects are reversible and 
withdrawal of the inducing or inhibiting agent results in reversal to the original 
rate of biotransformation (Park & Breckenridge, 1981). 
Most studies on hepatic microsomal enzyme system-catalyzed 
metabolism of drugs have been restricted to laboratory animals such as rats and 
rabbits. Relatively little is known about comparative drug metabolism in food-
producing mammalian species (Dalvi et al, 1987). Often, wide differences in 
physiological or metabolic capabilities exist among species that are classified 
as closely related phylogenetically. This is especially so in the biotransformation 
and disposition of xenobiotics (Smith et al, 1984). Inter-species variations 
make it difficult to extrapolate information from one species to another. This 
difficulty may be due to the presence of multiple enzyme forms and the role of 
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extra-hepatic tissues such as the rumen wall Whictl is tlie s'ite· of significant 
biotransformation (Watkins & Klaassen, 1986). Cattle differ widely from rats 
in having lower activity of glutathione-S-transferase for sulfobromophthalein 
and 1,2-dichloro-4-nitrobenzene and remarkably high activities of styrene oxide 
hydrolase, ethoxyresorufin o-deethylase, 2-naphthol sulfotransferase and p-
aminobenzoic acid acetyltransferase (Smith et al, 1984). 
Antipyrine 
Antipyrine is widely used as a model drug for studying changes in 
hepatic drug metabolism. Antipyrine is rapidly absorbed through the gut and 
then distributed in total body water. There is negligible plasma protein binding 
of antipyrine. Metabolism of antipyrine is almost exclusively by the hepatic 
microsomal enzyme system and is not influenced by hepatic blood flow. Phase 
1 metabolism is the rate limiting step in antipyrine biotransformation. Total 
body clearance for antipyrine is equal to antipyrine metabolic clearance (Park 
& Breckenridge, 1981; Depelchin et al, 1988). Metabolism of antipyrine occurs 
by a number of different isozymes of cytochrome P-450 in rats (lnaba et al, 
1980). In calves, however, hydroxylation is the major metabolic pathway of 
antipyrine. Biotransformation of antipyrine in man involves N-methylation and 
hydroxylation (Depelchin et al, 1988). Changes in antipyrine disposition may 
be used to measure hepatic microsomal enzyme induction in an organism and 
plasma half-life or clearance of antipyrine is often used to assess an individual's 
capacity to metabolize other drugs (Park & Breckenridge, 1981). For example, 
the half-lives of antipyrine are considerably longer in patients with liver disease 
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than in patients not suffering from liver disease (lnabJ3 et al, 1980). In a given 
subject, tests consist of measuring antipyrine clearance in a controlled, 
environmentally stable state and again after a single environmental ,change is 
imposed. !These tests have been applied to identify and ,quantitate the impact 
of many conditions and factors on hepatic metabolism of antipyrine. Under 
stable environmental condititions, disposition, of antipyrine is highly 
reproducible, therefore, each subject can serve, as its own control (Vesell, 
1979; Depelchin et al, 1987). 
A wide range of inducing agents such as drugs, pesticides, and nutrients 
have been shown to increase antipyrine clearance in humans and other animals 
{Park & Breckenridge, 1981). Phenobarbital has been shown to shorten the 
half-life of antipyrine (lnaba et al, 1980). Dexamethasone phosphate has been 
shown to stimulate the metabolism of antipyrine by activating cytochrome P-
450. This increase in metabolism results in a shortening of antipyrine 
elimination half-life in calves (Depelchin et al, 1987). Griseofulvin stimulates 
an increase in liver weight which results in induction of antipyrine metabolism 
(Depelchin et al, 1987). Promethazine, a phenothiazine derivative, significantly 
increased clearance of antipyrine. However, the decrease in the half-life of 
antipyrine was not significant since there was an observed change in the 
apparent volume of distribution (Taylor & Houston, 1985). Phenytoin has been 
shown to significantly reduce the half-life of antipyrine in epileptic subjects 
(Park & Breckenridge, 1981). 
Antipyrine has been reported to be a mild enzyme inducer in man, which 
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is one of the disadvantages to its use as a ~model drug? Daily administration of 
antipyrine for a 14 day period produces an induction of hepatic microsomal 
enzyme system. Therefore, long term administration of antipyrine can stimulate 
its own metabolism and has been shown to increase the rate of elimination of 
diazepam and warfarin. Since antipyrine requires 14 days of daily administration 
to produce an induction, intermittent administration of antipyrine is unlikely to 
result in a change in the hepatic microsomal enzyme systems (Ohnhaus et al, 
1979; Park & Breckenridge, 1981). 
Erythromycin 
The macrolide antibiotic, erythromycin, is used in the treatment of gram-
positive and some gram-negative bacterial infections. Erythromycin is highly 
lipid soluble, widely distributed in the body (Burrows, 1980), and slightly bound 
to serum proteins (Ziv & Sulman, 1972). Metabolism of erythromycin occurs 
primarily in the liver by demethylation and is followed by biliary excretion 
(Burrows, 1980; Manzo et al, 1980). 
In the rat, hepatic microsomal metabolism and biliary excretion of 
erythromycin was increased by phenobarbital. This increase in metabolism and 
excretion results in markedly lower concentrations of erythromycin in tissues 
and serum (Manzo et al, 1980). Theophylline was found to cause a 30% 
decrease in area under the serum erythromycin concentration time curve, 
possibly resulting from increased hepatic blood flow (Ludden, 1985). 
Derivatives of erythromycin have been reported to be potent inducers of 
hepatic cytochrome P-450 (Sartori et al, 1985). The elimination of 
l1· 
methylprednisolone has been reported to be inhibited*by er~,rt_J)_romycin (R~isz et 
al, 1983). 
Avermectins 
Avermectins are natural products of the microorganism Streptomyces 
avermitilis. This microbe was isolated at Kitasato Institute from a soil sample 
collected in Japan. Studies using the product indicated at least an eight-fold 
increase in activity against Nematospiraoides dubis in mice and there was no 
notable toxicity. The complex, which was named avermectin, was then 
isolated and identified {Burg et al., 1979). 
Avermectins are glycosidic derivatives of pentacyclic 16-member 
lactones but lack the antibacterial properties associated with macrolide 
antibiotics. The compounds were isolated by solvent extraction of the mycelia. 
Reverse phase high pressure liquid chromatography separation and mass 
spectra examination indicated the existence of two series of compounds 
designated A and B. The A-series compounds have a methoxy group at the 
5-position and are generally less effective than those of the 8-series. For this 
reason, the A-series have never been developed for use. Within the two 
series, there exist~ two structural subsets designated 1 and 2 and the presence 
of minor homologues a and b. The eight components were designated A,a 
through B2b (Aibers-Schonberg et al., 1981; Campbell et al, 1983). The 
compounds of subset-1 posses an olefinic bond between carbon 22 and 23 
while in subset-2, this linkage is hydrated with the hydroxyl group found at the 
23 position. The difference in conformation has a profound effect on the ring 
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bearing these functionalities, causing subtle changes in ·bioactivity. Upon oral 
administration, avermectin 81 had been determined to be more active than 
avermectin 82 while the converse was true when each was administered 
parenterally. The nonproprietary name ivermectin contains at least 80 percent 
22, 23-dihydroavermectin 818 and not more than 20 percent 22, 
23-dihydroavermectin B,b (Chabala et al., 1980). 
lvermectin has low solubility in water and is lipophilic. In cattle the half-
life of ivermectin was found to be 2.8 days, with a large volume of distribution 
(1.91/kg) and a rapid distribution phase. This large volume of distribution 
results in a shift in the equilibrium distribution from the central compartment 
toward the peripheral compartment (Lo et al, 1985). Fat and liver contain the 
highest tissue residue levels while brain and blood have the lowest. Depletion 
half-lives of ivermectin in fat and liver were 4-8 days (Chiu et al, 1990). The 
major tissue residue of ivermectin in liver, fat, muscle and kidney was the 
unaltered drug (Chiu et al, 1986). In cattle, ivermectin is biotransformed in the 
liver to produce polar metabolites which are esterified to nonpolar entities. 
These nonpolar entities are stored in fat and can be readily hydrolyzed back to 
the polar metabolites. Levels of the nonpolar metabolites could be detected in 
fat tissues of steers after the animals were withdrawn from the drug for 28 
days (Chiu et al, 1988). The major route of excretion was in feces. In cattle, 
high levels of ivermectin found in bile suggest that biliary excretion is an 
important route of elimination (Chiu et al, 1990). 
In mammals, ivermectin has a wide margin of safety and when 
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administered at the recommended dose there are no indications of adverse 
effects. However, at 40 times the recommended dose, toxicity and death were 
observed. No fetal abnormalities were seen in cattfe treated subcutaneously 
during pregnancy at twice the recommended dosage (Campbell, 1981; 
Campbell et al, 1983). 
Experimental Goals and Design 
As discussed previously, xenobiotics that have a relatively long biological 
half-life and are lipophilic are thought to have the potential to act as enzyme 
inducers (Anadon, 1982). lvermectin is lipophilic and has a relatively long half-
life in cattle and other animals. Based upon these properties, ivermectin 
appears to be a potential enzyme inducer. Therefore, this study was carried 
out to ascertain the effect of ivermectin on biotransformation of model drugs 
in cattle. One of the model drugs, erythromycin was selected because it is one 
of the drugs of choice for treatment of bovine respiratory diseases and might 
be used in conjunction with ivermectin in animals newly introduced to 
feedyards. It is also biotransformed in the body and subject to possible 
changes in hepatic mixed-function oxidase activity. Antipyrine was used 
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Figure 1. Oxidation of a xenobiotic by cytochrome P-450 electron transport 
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CHAPTER II 
EFFECTS OF IVERMECTIN ON ANTIPYRINE AND ERYTHOMYCIN 
DISPOSION IN CATTLE 
Introduction 
Drug interactions commonly occur when two or more drugs are 
administered simultaneously or when animals are exposed to xenobiotics 
present in food, water, and air. Such interactions may modify the biological 
activity of a xenobiotic by altering absorbtion, distribution, metabolism, or 
elimination. Interactions are particularly likely when a xenobiotic is capable of 
inducing or inhibiting hepatic metabolic enzymes (Hayes & Borzelleca, 1985). 
As the rate of biotransformation is altered, the duration and intensity of drug 
action may be affected (Conney, 1967). Lipophilicity, binding to cytochrome 
P-450, and relatively long half-life are three common characteristics of hepatic 
metabolic enzyme inducers such as phenobarbital (Anadon, 1982). 
lvermectin, a macrolactone with antiparasitic properties, is a lipophilic 
compound which is metabolized in the liver and excreted in the bile of cattle 
(Campbell et al, 1983). Chiu et al, (1990) reported that ivermectin has a 
relatively long half-life (2.8 days); the depletion half-life in fat and liver residues 
was 4-8 days and metabolites have been detected in fat tissues of steers 28 
days after vyithdrawal (Chiu et al, 1988). These dispositional characteristics, 
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which are similar to those of recognized enzyme inducers, suggest that 
ivermectin may induce the metabolism of concurrently administered drugs. 
In order to evaluate the enzyme .inducing potential for ivermectin, two 
model drugs were selected. The objective of the study was to determine 
whether ivermectin acts as an enzyme inducer or inhibitor by studying the 
effect of intramuscular administration of ivermectin on the pharmacokinetic 
disposition of the two model drugs, erythromycin and antipyrine. Erythromycin 
is a macrolide antibiotic commonly used in cattle. It is eliminated by hepatic 
metabolism and biliary excretion (Burrows, 1980; Manzo et al, 1980) and 
represents a clinically relevant drug which may be affected by concurrent 
administration of ivermectin. Antipyrine is eliminated exclusively via hepatic 
biotransformation and is widely used as an experimental model drug for 
identifying changes in the rate of drug metabolism (Park & Breckenridge, 1981; 
Depelchin, 1988). 
Materials and Methods 
Experiment 1 
Five mixed-breed heifer calves of approximately 5 months of age and 
initial body weights of 65.9 to 115.9 kg were maintained on prairie hay and a 
commercial grain mixture containing 14% protein (A&M Milling, Stillwater, OK) 
and water ad libitum. Calves were penned outdoors. 
A cross-over experimental design was used to investigate the effect of 
ivermectin on erythromycin pharmacokinetics. Calves were divided into two 
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groups. Three calves in group 1 received a single. i. v. dose .of,.er,ythromycin 
(Gallimycin 200mg/ml, CEVA Labs, .Overland Park, KS) (15mg/kg bodywt.) via 
a jugular catheter to establish baseline parameters. Two weeks later, group 1 
calves were given a single i.m. dose of ivermectin (1% w/v cattle injection, 
lvomec, MSD Agvet, Rahway, NJ) (1 mg/5kgtbody wt.) and a single i.m. dose 
of erythromycin ( 15mg/kg body wt.). On days 2, 4, and 13 following the 
treatment with ivermectin, each calf received the same dose of erythromycin 
i.v. via a jugular catheter. The two calves in group 2 were initially given a 
single i.m. dose of ivermectin (1 mg/5kg body wt.) and a single i.m. dose of 
erythromycin (15mg/kg body wt.). Thereafter, erythromycin was administered 
i. v. via a jugular catheter on days 2, 4, and 13 following the initial ivermectin 
dose. Two weeks after the end of the 13 day sampling period, group 2 calves 
were given the single i.v. dose of erythromycin to establish baseline 
parameters. Because of an adverse response in some of the calves given 
erythromycin i.v. on day 2, it was thereafter diluted 1:1 with saline and 
administered in small increments over a minute on days 4 and 13. Blood was 
collected from a contralateral jugular catheter at 0, 2, 5, 10, 20, 30, 45 and 
60 minutes and 2, 3, 4, 6, 8, 12, and 16 hours following each i.v. 
administration of erythromycin. Serum was harvested and stored at -20°C until 
analysis. 
Experiment 2 
Five bull and one heifer Hereford calves with an initial body weight of 
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75.0 to 140.9· kg were maintained and housed as .previously <described. 
Antipyrine (10% solution, Sigma Chemical Co., St. Louis, MOl (20 mg/kg 
body wt.) was administered to each calfr, via a jugular catheter. Blood was 
collected from a contralateral indwelling·jugular catheter at 0, 2, 5, 10, 15, 20, 
30, 45, 60 and 90 minutes and 2, 3, 4, 5, 6, 7, and 8 hours after 
administration of antipyrine. Serum was harvested and stored as previously 
described. Two weeks later, each calf was given ivermectin i.m. (1 o/o w/v 
cattle injection, MSD Agvet, Rahway, NJ) (1 mg/5kg body wt.) on day 1. On 
days 3 and 17, each calf was administered antipyrine i.v., blood was collected 
as previously described. Serum was harvested and frozen at -20° until assayed. 
Drug Assay 
Erythromycin. Erythromycin concentrations were determined using the 
microbial assay method of Bennett et al, (1966); an agar-gel diffusion method 
employing Micrococcus luteus ATCC 9341 as the test organism (Burrows, 
1985) with a detectability level of approximately 0.3 pg/ml. Standard solutions 
were prepared in calf serum by appropriate serial dilutions of drug. Standards 
and serum samples were analyzed in duplicate with samples undiluted and 
diluted to 1:2 with serum. The measured width of zones from serum samples 
were converted to concentrations, using standard curves developed for each 
81-well agar plate. 
Antipyrine. Antipyrine concentrations in serum were quantitated using a 
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modification of the method reported by Clarke et al, (1985). Briefly, 40-pl of 
5 N sodium hydroxide and 2 ml of ethyl acetate containing 2.5 ppm phenacetin 
as the internal standard were added to 0.2 ml of serum and vortexed 
immediately for 30 seconds. The combination was separated by centrifugation 
at 600 x g for 5 minutes and the organic supernatant transferred to 
a chromatography vial. Standards (0, 0.5, 1, 2.5, 5, 10, 25, 50 ppm) were 
prepared by dissolving appropriate amounts of antipyrine in 0.2 ml of serum. 
The test sera and standards were subjected to the same analytic procedure. 
Antipyrine concentrations were quantitated by injecting 4-pl samples of 
supernatant into a gas chromatograph (Tracor 565, Austin, TX) with a 30m, 
0.53mm ID megabore capillary column with a 1.0 pm film of 50% 
phenylmethyl polysiloxane (0817, J&W Scientific, Folsom, CA). The column, 
injection port, and nitrogen-phosphorus detector temperatures were 180, 230, 
and 250° C, respectively. The flow rate for helium carrier gas was 10 ml/min; 
for detector hydrogen, 2.5ml/min; and for air, 120 ml/min. 
Pharmacokinetics 
Coefficients and exponents ofthe disposition curves were obtained using 
a computer program for modeling and simulation of pharmacokinetic data 
(Bourne, 1986). Determination of appropriate compartmental model was based 




Pharmacokinetic parameters for which a: normal distribution cannot be 
assumed (elimination half-life, volume of distribution, total'body clearance) were 
rank transformed (Conover & I man, 1981) prior to analysis. The ranked and 
mean nonranked parameter values were analyzed 'bY the general linear model 
and Dunnett's test (p < 0.05) to compare treatment to baseline values. For 
experiment 1, pre-ivermectin and post-ivermectin baseline B and 8 values were 
analyzed using the general linear model and LS means to determine the validity 
of the cross-over design (Steel & Torrie, 1980}. 
Results 
The serum concentration-time disposition data were described using a 
two-compartment open model and the bi-exponential equation: 
Cp = Ae-at + se-Pt 
where Cp is the concentration in serum at time t; A and 8 are the biphasic 
zero-time intercepts; e is the natural logarithm base; and a and Pare the rate 
constants related to the disposition and elimination phases, respectively 
(8aggot; 1977}. 
Pharmacokinetic parameters describing erythromycin disposition are 
presented in Table 1. The semi-logarithmatic plots of the concentration-time 
curves for individual treatments are presented in the appendix (figures 1-4}. 
There were no significant differences between baseline values and those 
calculated after ivermectin treatment, except for an increase in total body 
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clearance rate on day 4. The cross-over design pretreatment and p'Osttreatment 
baseline values were not significantly different. Immediately following 
administration of erythromycin, an adverse systemic effect was observed in 
some calves characterized by dyspnea, polypnea, and tremors. This effect was 
alleviated when the erythromycin was diluted with saline and administered 
slowly in small increments. 
The pharmacokinetic values determined for antipyrine are presented in 
Table 2 and the semi-logarithmatic concentration-time curves of the individual 
treatments are presented in the appendix (figures 5-8). There were no 
differences between antipyrine kinetics when baseline and post ivermectin 
parameters were compared. 
Discussion 
The parmacokinetic values for erythromycin and antipyrine are consistent 
with published values (Baggot & Gingerich, 1976; Burrows, 1985; Burrows et 
al, 1989; Tufenkji et al, 1988) and in general were not affected by ivermectin. 
The only significant difference noted was for erythromycin total body clearance 
on day 4. However, this apparent increase in CIB may not be meaningful. The 
slope of the elimination phase (f!,) and volume of distribution (Vd), which are 
used in the determination of the clearance rate, were apparently increased on 
day 4 but the changes were not significant. An additional factor contributing 
to the difference in clearance rate may be the change in the method of 
administration of erythromycin. Erythromycin given for baseline determination 
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and on ·day 2, was administered as an·i.v. ,bolus while on days ,A and 13 it was 
diluted 1:1 with saline and administered in small ··increments over one minute. 
Since the erythromycin was administered slowly on day 4, the :distribution 
phase may have been lengthened accordingly, thereby producing an apparent 
increase in the volume •of distribution (Vd), and thus making the elimation rate 
appear to be increased. The combination of these e·f.fects might lead to an 
apparent significant increase in the clearance rate (Cig). The change in the 
method of erythromycin administration was made in an attempt to prevent the 
peracute systemic reactions observed. The calves showed signs of dyspnea, 
polypnea, and tremors immediately after rapid i.v. administration of the 
concentrated preparation. The dilution of erythromycin and slow administration 
in small increments alleviated the reaction and the calves showed no adverse 
signs when this method was employed on days 4 and 13. This acute reaction 
to antibiotics is similar to that reported previously for chloramphenicol and 
oxytetracycline (Gross et al, 1981; Burrows, 1984; Burrows et al, 1988; 
Sangiah & Burrows, 1989) and erythromycin (Burrows et al, 1989). 
Drug elimination is dependent upon several processes. In the case of 
antipyrine, elimination follows hepatic uptake, biotransformation and 
subsequent clearance in urine. Phase 1 metabolism is the rate limiting step in 
antipyrine elimination, which is independent of hepatic blood flow (Vesell, 
1979). Thus, the lack of effect of ivermectin on disposition of antipyrine is 
likely reflective of an absence of effect on basic hepatic biotransformation 
pathways including cytochrome P-450. This may be further focused 
26 
specifically on hydroxylation pathways. Whereas antipyrine metabolism in man 
and laboratory animals results in several important metabolites, ie 3-
hydroxymethyl-antipyrine,4-hydroxyantipyrineand norantipyrine (Teunissen et 
al, 1983a; Teunissen et al, 1983b) only 4-hydroxyantipyrine is of significance 
in ruminants (Tufenkji et.al, 1988). Jvermectin apparently does not affect this 
hydroxylation pathway. The N-demethylation pathway involved with 
biotransformation of antipyrine to norantipyrine is not an important pathway in 
calves. 
Erythromycin is more useful as a model drug for the purpose of 
evaluating the N-demethylation pathway. In rats, erythromycin is taken up by 
hepatocytes, undergoes N-demethylation and is eliminated in bile, probably as 
conjugated metabolites (Lee et al, 1956). In addition, substantial amounts of 
active parent drug are also eliminated in bile and urine (Twiss et al, 1956; 
Wyman et al, 1968}. Although these pathways have not been confirmed for 
cattle, there is little reason to believe they are less functional than in rats since 
N-demethylase activity for other substrates is quite comparable between cattle 
and rats (Smith et al, 1984; Watkins & Klaassen, 1986). Futhermore, liver 
disease limiting antipyrine disposition also limits erythromycin disposition 
(Burrows et al, 1992). Thus, it appears that neither the antipyrine 
hydroxylation pathway nor the erythromycin N-demethylation pathway is 
affected by ivermectin. However, in the case of erythromycin, an additional 
factor of importance is the role of active biliary secretion of both the parent 
compound and the metabolite. Nevertheless, the more important overall effects 
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indicate a lack of interaction. 
Based on the present results and until further inves.t.igatiorys are carried 
out, there is little reason for undue concern regarding the potential for 
ivermectin to affect disposition of other drugs with which it might be 
concurrently administered. However, to more conclusively establish a lack of 
effect by ivermectin on xenobiotic disposition, the pharmacokinetics of 
representative agents, subject to other biotransformation pathways such as 
deacylation, nitro reduction, and oxidation should be determined in the presence 
of ivermectin. Compounds of particular importance include anesthetics, 
antibiotics subject to biotransformation, steroidal hormones and various 
antiparasitic agents. 
The results point out the limitations of using generalities to predict 
specific drug interactions. In this case, high lipid solubility with extensive 
biotransformstion and very long t 112B led to the prediction that the disposition 
of other extensively biotransformed drugs would be affected. The lack of 
effect may be indicative of an absence of influence on biotransformation in 
general, however, erythromycin and antipyrine are representative of only two 
of several pathways. While it is probably reasonable to assume that results 
based on two divergent biotransformation and elimination pathways are 
indicative of an overall lack of disposition interaction potential, some caution 
is warranted. Because of the many different isozymes of cytochrome P-450, 
broad extrapolation may not be entirely justified. 
In the present studies, the objective was to determine if ivermectin 
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influenced the disposition of antipyrine and erythromycin. The converse may 
also be an important consideration, particularly since erythromycin has been 
shown to inhibit and in a few cases induce hepatic biotransformation (Ludden, 
1985; Sartori, 1985). These effects require prolonged exposure with repeated 
dosage longer than 5 days, in contrast to the present studies where 
erythromycin was given intermittently. 
Table 1. A comparison of the mean ±so or median ±mdev pharmacokinetic values for erythromycin (15mg/kg BW) i.v. using a two 
compartmental model following treatment with ivermectin (1 mg/5kg BW) i.m. (n = 5) 
Treatments with ivermectin 
Determinants before ivermectin 3 days after 5 days after 14 days after 
A, ,ug/ml 52.89 ± 47.46 45 .94 ± 14.68 65.42 ± 87 .41 64.69 ± 34.97 
B, ,ug/ml 10.40 ± 1.83 7.59 ± 4.57 5.26 ± 3.98 8.54 ± 6.83 
a, h'1 9.36 ± 8.25 10.31 ± 5.83 15.51 ± 12.89 18.30 ± 4.45 
B, h-1 0.22 ± 0.06 0 .24 ± 0.07 0.25 ± 0.10 0.13 ± 0.12 
t112B• h-1' 2.94 ± 1.95 2.41 ± 0 .81 2.98 ± 1.03 3.57 ± 2.88 
C0 p, ,L/Q/ml' 42.39 ± 28.24 47.98 ± 12.12 33.47 ± 46.71 89 .30 ± 24.46 
Vc, ml/kg' 353.84 ± 111.42 312.64 ± 54.79 448.18 ± 236.33 167.98 ± 126.31 
Kz1• h-1 1.78 ± 1.05 1.53 ± 0 .82 1.60 ± 0.68 2.00 ± 0.49 
K.1, h-1 1.23 ± 1.07 1.66 ± 0.51 2.42 ± 1.94 1.37 ± 0.88 
K12, h'1 6.57 ± 6.79 7.36 ± 4 .94 11.74 ± 10.67 15.08 ± 4.83 
v d(araa) t ml/kg. 1244.50 ± 168.72 1431.11 ± 1265.01 3055.71 ± 1484.48 1789.50 ± 1790.02 
vd( .. )r ml/kg' 1074.74 ± 153.67 1288.45 ± 947.62 2499.22 ± 1239.77 1591.10 ± 1749.80 
Cia, ml/h/kg' 285.89 ± 49.80 429.30 ± 144.67 709.87 ± 382.50 .. 347.18 ± 59.94 
Median deviation determined by I:lx-ml/n; •median values; ••significantly different from the control (p.5_0.05). Bagott, J .D. (1977) 
Table 2. A comparison of the mean ± so or median ± mdev pharmacokinetic values for antipyrine (20mg/kg BW) i.v. using 






v d(&le&) I m I/ kg 0 
vdlss)• ml/kg' 
Cl 13, ml/h/kg" 
before ivermectin 
51.00 ± 17.28 
28.49 ± 10.67 
11.24 ± 8.94 
0 .27 ± 0.08 
2.56 ± 0.63 
76.38 ± 17.84 
263.22 ± 66.63 
4 .18 ± 3 .36 
0.74 ± 0.24 
6.60 ± 5.71 
679.51 ± 211.87 
618.36 ± 212 .46 
175.22 ± 45.11 
Treaments with ivermectin 
3 days after 
76.25 ± 35.20 
30.58 ± 5.97 
9.70 ± 7.25 
0.25 ± 0.03 
2.84 ± 0.27 
93.93 ± 19.33 
213.17 ± 30.71 
2.72 ± 0.94 
0.82 ± 0.31 
6.40 ± 6.24 
634.88 ± 80.67 
597.45 ± 72.79 
156.87 ± 15.39 
•median values; median deviation determined by Ilx-mlfn; Bagott, J.D. (1977) 
1 7 days after 
63.22 ± 25.13 
29.07 ± 9.79 
12.10 ± 6.68 
0.29 ± 0 .09 
2.54 ± 0.66 
106.10 ± 24.28 
188.82 ± 77 .83 
3.86 ± 1.85 
0.91 ± 0.43 
7.62 ± 4.68 
615.33 ± 201.52 
574.81 ± 187.7 
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CHAPTER Ill 
SUMMARY AND CONCLUSIONS 
The parmacokinetic values for erythromycin and antipyrine are consistent 
with published values (Baggot & Gingerich, 1976; Burrows, 1985; Burrows et 
al, 1989; Tufenkji et al, 1988) and in general were not affected by ivermectin. 
The only significant difference noted was for erythromycin total body clearance 
on day 4. However, this apparent increase in Cis may not be meaningful. The 
slope of the elimination phase (B) and volume of distribution (Vd), which are 
used in the determination of the clearance rate, were apparently increased on 
day 4 but the changes were not significant. An additional factor contributing 
to the difference in clearance rate may be the change in the method of 
administration of erythromycin. Erythromycin given for baseline determination 
and on day 2, was administered as an i.v. bolus while on days 4 and 13 it was 
diluted 1:1 with saline and administered in small increments over one minute. 
Since the erythromycin was administered slowly on day 4, the distribution 
phase may have been lengthened accordingly, thereby producing an apparent 
increase in the volume of distribution (Vd), and thus making the elimation rate 
appear to be increased. The combination of these effects might lead to an 
apparent significant increase in the clearance rate {Cis). The change in the 
method of erythromycin administration was made in an attempt to prevent the 
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peracute systemic reactions observed. The ,calves,showed signs of dyspnea, 
polypnea, and tremors immediately after rapid i.v; administration of the 
concentrated preparation. The dilution of erythromycin and slow administration 
in small increments alleviated the reaction and the calves showed no adverse 
signs when this method was employed on days 4 and 13. This acute reaction 
to antibiotics is similar to that reported previously for chloramphenicol and 
oxytetracycline (Gross et al, 1981; Burrows, 1984; Burrows et al, 1988; 
Sangiah & Burrows, 1989) and erythromycin (Burrows et al, 1989). 
Drug elimination is dependent upon several processes. In the case of 
antipyrine, elimination follows hepatic uptake, biotransformation and 
subsequent clearance in urine. Phase 1 metabolism is the rate limiting step in 
antipyrine elimination, which is independent of hepatic blood flow (Vesel!, 
1979). Thus, the lack of effect of ivermectin on disposition of antipyrine is 
likely reflective of an absence of effect on basic hepatic biotransformation 
pathways including cytochrome P-450. This may be further focused 
specifically on hydroxylation pathways. Whereas antipyrine metabolism in man 
and laboratory animals results in several important metabolites, ie 3-
hydroxymethyl-antipyrine, 4-hydroxyantipyrine and norantipyrine (Teunissen et 
al, 1983a; Teunissen et al, 1983b) only 4~hydroxyantipyrine is of significance 
in ruminants (Tufenkji et al, 1988). lvermectin apparently does not affect this 
hydroxylation pathway. The N-demethylation pathway involved with 
biotransformation of antipyrine to norantipyrine is not an important pathway in 
calves. 
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Erythromycin is more useful as a model drug for the purpose of evaluating the 
N-demethylation pathway. In rats, erythromycin is taken up by hepatocytes, 
undergoes N-demethylation and is eliminated in bile, probably as conjugated 
metabolites (Lee et al, 1956). In addition, substantial amounts of active parent 
drug are also eliminated in bile and urine (Twiss et al, 1956; Wyman et al, 
1968). Although these pathways have not been confirmed for cattle, there is 
little reason to believe they are less functional than in rats since N-demethylase 
activity for other substrates is quite comparable between cattle and rats (Smith 
et al, 1984; Watkins & Klaassen, 1986). Futhermore, liver disease limiting 
antipyrine disposition also limits erythromycin disposition (Burrows et al, 1992). 
Thus, it appears that neither the antipyrine hydroxylation pathway nor the 
erythromycin N-demethylation pathway is affected by ivermectin. However, 
in the case of erythromycin, an additional factor of importance is the role of 
active biliary secretion of both the parent compound and the metabolite. 
Nevertheless, the more important overall effects indicate a lack of interaction. 
Based on the present results and until further investigations are carried 
out, there is little reason for undue concern regarding the potential for 
ivermectin to affect disposition of other drugs with which it might be 
concurrently administered. However, to more conclusively establish a lack of 
effect by ivermectin on xenobiotic disposition, the pharmacokinetics of 
representative agents, subject to other biotransformation pathways such as 
deacylation, nitro reduction, and oxidation should be determined in the presence 
of ivermectin. Compounds of particular importance include anesthetics, 
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antibiotics subject to biotransformation, steroidal hormones and various 
antiparasitic agents. 
The results point out the limitations of using generalities to predict 
specific drug interactions. In this case, high lipid solubility with extensive 
biotransformstion and very long t 1128 led to the prediction that the disposition 
of other extensively biotransformed drugs would be affected. The lack of 
effect may be indicative of an absence of influence on biotransformation in 
general, however, erythromycin and antipyrine are representative of only two 
of several pathways. While it is probably reasonable to assume that results 
based on two divergent biotransformation and elimination pathways are 
indicative of an overall lack of disposition interaction potential, some caution 
~s warranted. Because of the many different isozymes of cytochrome P-450, 
broad extrapolation may not be entirely justified. 
In the present studies, the objective was to determine if ivermectin 
influenced the disposition of antipyrine and erythromycin. The converse may 
also be an important consideration, particularly since erythromycin has been 
shown to inhibit and in a few cases induce hepatic biotransformation (Ludden, 
1985; Sartori, 1985). These effects require prolonged exposure with repeated 
dosage longer than 5 days, in contrast to the present studies where 
erythromycin was given intermittently. 
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Figure 1. Computer generated curves of erythromycin (15 mg/kg) i.v. versus 




























Figure 2. Computer generated curves of erythromycin (15 mg/kg) i.v. versus 
































Figure 3. Computer generated curves of erythromycin (15 mg/kg) i.v. versus 





























Figure 4. Computer generated curves of erythromycin (15 mg/kg) i.v. versus 




















0 1 2 3 4 5 6 7 8 
Time (h) 
Figure 5. Computer generated curves of antipyrine (20 mg/kg) i. v. versus 
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Figure 6. Computer generated curves of antipyrine (20 mg/kg) i. v. versus 
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Figure 7. Computer generated curves of antipyrine (20 mg/kg) i.v. versus 
time for day 17. Points represent mean observed ± so values in 
cattle. 
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